Short Interest in Briacell Therap (NASDAQ:BCTX) Expands By 81.5%

Briacell Therap (NASDAQ:BCTX) was the recipient of a large increase in short interest in August. As of August 31st, there was short interest totaling 723,836 shares, an increase of 81.5% from the August 15th total of 398,913 shares. Currently, 8.4% of the company’s shares are sold short. Based on an average daily volume of 967,776 shares, the days-to-cover ratio is currently 0.7 days.

Briacell Therap Price Performance

BCTX opened at $3.56 on Thursday. Briacell Therap has a 12-month low of $2.60 and a 12-month high of $14.68. The stock has a market capitalization of $30.97 million, a PE ratio of -0.45 and a beta of 1.10. The firm’s fifty day moving average price is $3.62 and its 200 day moving average price is $3.71.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Briacell Therap in a research report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.